PG-2TZ is a synthetic 39-amino-acid research peptide studied as a dual-receptor agonist, with activity at the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor. This dual-receptor profile is the defining characteristic of PG-2TZ research, distinguishing it from single-receptor incretin peptides and connecting it to the broader class of multi-receptor metabolic agonists studied in incretin pharmacology.
What Is PG-2TZ?
PG-2TZ is a synthetic peptide research compound with a 39-amino-acid sequence based on a native incretin hormone backbone, modified with two non-proteinogenic amino acid residues and a fatty-diacid moiety attached through a linker. This fatty-acid modification promotes reversible albumin binding, which extends the compound’s circulating half-life relative to unmodified incretin peptides, a structural feature central to its research profile.
The two principal receptor relationships relevant to PG-2TZ research are:
- PG-2TZ → GIP receptor (GIPR)
- PG-2TZ → glucagon-like peptide-1 receptor
Together, these two receptor relationships form the basis for studying PG-2TZ as a dual-receptor agonist spanning two complementary incretin signaling systems.
Mechanism of Action
GIP Receptor Signaling
The GIP receptor is a class B G protein-coupled receptor involved in nutrient-responsive incretin signaling. Research has examined PG-2TZ’s binding affinity at GIPR and its downstream effect on insulin secretion and adipocyte signaling, positioning GIPR activity as one half of the compound’s dual-receptor pharmacological profile.
Glucagon-Like Peptide-1 Receptor Signaling
The glucagon-like peptide-1 receptor is a second class B G protein-coupled receptor, activated by PG-2TZ alongside GIPR. Signaling through this receptor is studied in relation to glucose-dependent insulin secretion, glucagon suppression, gastric emptying, and appetite-related signaling. Research has examined how binding behavior at this receptor can differ biophysically from native hormone activity, a distinction studied for its relevance to receptor internalization and downstream signaling duration.
PG-2TZ → GIPR + glucagon-like peptide-1 receptor activation → adenylyl cyclase → cyclic AMP → insulin secretion / glucagon suppression
Why Dual-Receptor Activity Matters
A single-receptor agonist provides a model for studying one hormone-signaling pathway in isolation. PG-2TZ’s dual-receptor activity allows researchers to investigate how simultaneous activation of GIPR and the glucagon-like peptide-1 receptor produces signaling and metabolic effects distinct from either receptor alone, a research question with direct relevance to comparative incretin pharmacology.
GIPR + glucagon-like peptide-1 receptor activation → intracellular signaling → glucose-related pathways → insulin signaling → energy metabolism
PG-2TZ Research Areas
PG-2TZ and Glucose Regulation
Research has examined receptor-mediated effects on insulin secretion, glucagon suppression, and glucose handling, providing a research model for studying how combined GIPR and glucagon-like peptide-1 receptor activation relates to glucose-related metabolic pathways.
PG-2TZ and Energy Metabolism
Research has connected PG-2TZ’s dual-receptor activity to metabolic signaling involving nutrient availability, energy balance, and substrate utilization, relevant to laboratory research examining hormone-receptor interaction with cellular energy metabolism.
PG-2TZ and Incretin Research
Incretins are hormone signals released in response to nutrient intake and involved in metabolic communication. PG-2TZ provides a research model for studying how coordinated activation of two incretin-related receptors, GIPR and the glucagon-like peptide-1 receptor, influences downstream signaling relative to single-incretin agonists.
PG-2TZ and Receptor Pharmacology
PG-2TZ is relevant to receptor pharmacology research examining ligand-receptor binding, receptor selectivity, signaling bias, and comparative receptor activity. Structural research has examined how specific amino acid residues within the peptide sequence influence interactions with GIPR and the glucagon-like peptide-1 receptor individually.
Molecular Characteristics
PG-2TZ is a 39-amino-acid modified peptide based on a native incretin hormone sequence, incorporating two non-proteinogenic amino acid residues and a fatty-diacid modification connected through a linker. The fatty-acid component supports reversible albumin binding, contributing to an extended pharmacokinetic profile relative to unmodified incretin peptides.
Peptide sequence → structural modification → GIPR/glucagon-like peptide-1 receptor binding → signaling activity → pharmacological profile
Product Specifications
| Specification |
Details |
| Product Name |
PG-2TZ |
| Compound Type |
Synthetic research peptide |
| Peptide Length |
39 amino acids |
| Receptor Targets |
GIPR, glucagon-like peptide-1 receptor |
| Research Profile |
Dual-receptor agonist |
| Primary Research Areas |
Receptor pharmacology, peptide signaling, metabolic research |
| Form |
Lyophilized powder |
| Reported Quantity |
32.49 mg |
| Reported Purity |
99.695% |
| Testing Laboratory |
Janoshik |
The reported analytical results correspond to the specific laboratory-tested material and should not automatically be applied to other PG-2TZ batches.
Research Use Only
PG-2TZ is supplied strictly for laboratory research purposes. It is not intended for human or veterinary use and is not offered as a drug, dietary supplement, or therapeutic product. The information provided on this page describes biochemical and pharmacological research and should not be interpreted as a recommendation for human use, diagnosis, treatment, cure, or disease prevention.
